{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T20:16:45Z","timestamp":1789503405573,"version":"build-2803163510"},"reference-count":36,"publisher":"Public Library of Science (PLoS)","issue":"11","license":[{"start":{"date-parts":[[2020,11,19]],"date-time":"2020-11-19T00:00:00Z","timestamp":1605744000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/publicdomain\/zero\/1.0\/"}],"funder":[{"DOI":"10.13039\/100000050","name":"National Heart, Lung, and Blood Institute","doi-asserted-by":"publisher","award":["IAA-A-HL-14-007"],"award-info":[{"award-number":["IAA-A-HL-14-007"]}],"id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000005","name":"U.S. Department of Defense","doi-asserted-by":"publisher","award":["DAMD17-03-1-0107"],"award-info":[{"award-number":["DAMD17-03-1-0107"]}],"id":[{"id":"10.13039\/100000005","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"abstract":"<jats:p>Breast Cancer is the most common form of cancer in women worldwide, impacting nearly 2.1 million women each year. Identification of new biomarkers could be key for early diagnosis and detection. Vitronectin, a glycoprotein that is abundantly found in serum, extracellular matrix, and bone, binds to integrin \u03b1v\u03b23, and promotes cell adhesion and migration. Current studies indicate that patients with amplified vitronectin levels have lower survival rates than patients without amplified vitronectin levels. In this study, we focused on the role of vitronectin in breast cancer survival and its functional role as a non-invasive biomarker for early stage and stage specific breast cancer detection. To confirm that the expression of vitronectin is amplified in breast cancer, a total of 240 serum samples (n = 240), 200 from breast cancer patients and 40 controls were analyzed using the Reverse Phase Protein Array (RPPA) technique. Of the 240 samples, 120 samples were of African American (AA) descent, while the other 120 were of White American (WA) descent. Data indicated that there were some possible racial disparities in vitronectin levels and, differences also seen in the recurrent patient samples. Next, we tried to uncover the underlying mechanism which plays a critical role in vitronectin expression. The cellular data from four different breast cancer cell lines- MCF7, MDA-MB-231, MDA-MB-468, and HCC1599 indicated that the PI3K\/AKT axis is modulating the expression of vitronectin. We believe that vitronectin concentration levels are involved and connected to the metastasis of breast cancer in certain patients, specifically based on recurrence or ethnicity, which is detrimental for poor prognosis. Therefore, in this current study we showed that the serum vitronectin levels could be an early marker for the breast cancer survival and we also determine the cellular signaling factors which modulate the expression and concentration of vitronectin.<\/jats:p>","DOI":"10.1371\/journal.pone.0242141","type":"journal-article","created":{"date-parts":[[2020,11,19]],"date-time":"2020-11-19T13:52:29Z","timestamp":1605793949000},"page":"e0242141","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":41,"title":["Functional role of vitronectin in breast cancer"],"prefix":"10.1371","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2690-8178","authenticated-orcid":true,"given":"Alakesh","family":"Bera","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Madhan","family":"Subramanian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Karaian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Eklund","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Surya","family":"Radhakrishnan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nahbuma","family":"Gana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen","family":"Rothwell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harvey","family":"Pollard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hai","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Craig D.","family":"Shriver","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meera","family":"Srivastava","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2020,11,19]]},"reference":[{"issue":"6","key":"pone.0242141.ref001","doi-asserted-by":"crossref","first-page":"438","DOI":"10.3322\/caac.21583","article-title":"Breast cancer statistics, 2019","volume":"69","author":"CE DeSantis","year":"2019","journal-title":"CA Cancer J Clin"},{"key":"pone.0242141.ref002","unstructured":"The World Health Organization: statistics on breast cancer 2019 [cited 2019]. WHO statistics on breast cancer]. https:\/\/www.who.int\/cancer\/prevention\/diagnosis-screening\/breast-cancer\/en\/."},{"issue":"Suppl 2","key":"pone.0242141.ref003","first-page":"17","article-title":"Breast Cancer: Conventional Diagnosis and Treatment Modalities and Recent Patents and Technologies","volume":"9","author":"MI Nounou","year":"2015","journal-title":"Breast Cancer (Auckl)"},{"issue":"2","key":"pone.0242141.ref004","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1007\/s10549-017-4529-5","article-title":"Differential presentation and survival of de novo and recurrent metastatic breast cancer over time: 1990\u20132010","volume":"167","author":"JA Malmgren","year":"2018","journal-title":"Breast Cancer Res Treat"},{"issue":"7","key":"pone.0242141.ref005","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1002\/jcb.23111","article-title":"Integrin alphavbeta3 promotes vitronectin gene expression in human ovarian cancer cells by implicating rel transcription factors","volume":"112","author":"U Reuning","year":"2011","journal-title":"J Cell Biochem"},{"issue":"5","key":"pone.0242141.ref006","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1016\/S1357-2725(99)00005-9","article-title":"Vitronectin","volume":"31","author":"I Schvartz","year":"1999","journal-title":"Int J Biochem Cell Biol"},{"issue":"4","key":"pone.0242141.ref007","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1159\/000152941","article-title":"Vitronectin and its receptors partly mediate adhesion of ovarian cancer cells to peritoneal mesothelium in vitro","volume":"29","author":"L Heyman","year":"2008","journal-title":"Tumour Biol"},{"issue":"5","key":"pone.0242141.ref008","first-page":"721","article-title":"The alpha v beta 3 integrin \"vitronectin receptor\"","volume":"29","author":"MA Horton","year":"1997","journal-title":"Int J Biochem Cell Biol"},{"issue":"6","key":"pone.0242141.ref009","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1002\/ddr.20265","article-title":"Integrin alpha(v)beta(3)-Targeted Cancer Therapy","volume":"69","author":"Z Liu","year":"2008","journal-title":"Drug Dev Res"},{"issue":"4","key":"pone.0242141.ref010","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1038\/bjc.1998.86","article-title":"Expression of alphav integrins and vitronectin receptor identity in breast cancer cells","volume":"77","author":"T Meyer","year":"1998","journal-title":"Br J Cancer"},{"issue":"8","key":"pone.0242141.ref011","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.1158\/1535-7163.MCT-12-1249","article-title":"Discovery of new small molecules targeting the vitronectin-binding site of the urokinase receptor that block cancer cell invasion","volume":"12","author":"VE Rea","year":"2013","journal-title":"Mol Cancer Ther"},{"issue":"20","key":"pone.0242141.ref012","first-page":"5307","article-title":"Urokinase receptor interacts with alpha(v)beta5 vitronectin receptor, promoting urokinase-dependent cell migration in breast cancer","volume":"59","author":"MV Carriero","year":"1999","journal-title":"Cancer Res"},{"issue":"8","key":"pone.0242141.ref013","first-page":"1299","article-title":"Vitronectin binding to urokinase receptor in human breast cancer","volume":"3","author":"MV Carriero","year":"1997","journal-title":"Clin Cancer Res"},{"issue":"1","key":"pone.0242141.ref014","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1177\/1076029614531450","article-title":"Plasma Levels of Plasminogen Activator Inhibitor Type 1 and Vitronectin in Children With Cancer","volume":"22","author":"D Tugcu","year":"2016","journal-title":"Clin Appl Thromb Hemost"},{"issue":"1","key":"pone.0242141.ref015","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1038\/nrc2748","article-title":"Integrins in cancer: biological implications and therapeutic opportunities","volume":"10","author":"JS Desgrosellier","year":"2010","journal-title":"Nat Rev Cancer"},{"key":"pone.0242141.ref016","doi-asserted-by":"crossref","first-page":"39805","DOI":"10.1038\/srep39805","article-title":"A Comprehensive Evaluation of the Activity and Selectivity Profile of Ligands for RGD-binding Integrins","volume":"7","author":"TG Kapp","year":"2017","journal-title":"Scientific Reports"},{"issue":"1A","key":"pone.0242141.ref017","first-page":"79","article-title":"The relationship between bone metastasis from human breast cancer and integrin alpha(v)beta3 expression","volume":"25","author":"S Takayama","year":"2005","journal-title":"Anticancer Res"},{"issue":"Suppl 1","key":"pone.0242141.ref018","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1093\/milmed\/usz254","article-title":"Proteomic Analysis of Inflammatory Biomarkers Associated With Breast Cancer Recurrence","volume":"185","author":"A Bera","year":"2020","journal-title":"Mil Med"},{"issue":"Suppl 1","key":"pone.0242141.ref019","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1093\/milmed\/usy417","article-title":"Serum Biomarkers for Racial Disparities in Breast Cancer Progression","volume":"184","author":"M Srivastava","year":"2019","journal-title":"Mil Med"},{"issue":"7391","key":"pone.0242141.ref020","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1038\/nature11003","article-title":"The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity","volume":"483","author":"J Barretina","year":"2012","journal-title":"Nature"},{"issue":"7757","key":"pone.0242141.ref021","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1038\/s41586-019-1186-3","article-title":"Next-generation characterization of the Cancer Cell Line Encyclopedia","volume":"569","author":"M Ghandi","year":"2019","journal-title":"Nature"},{"issue":"7403","key":"pone.0242141.ref022","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1038\/nature10983","article-title":"The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups","volume":"486","author":"C Curtis","year":"2012","journal-title":"Nature"},{"key":"pone.0242141.ref023","doi-asserted-by":"crossref","first-page":"11479","DOI":"10.1038\/ncomms11479","article-title":"The somatic mutation profiles of 2,433 breast cancers refines their genomic and transcriptomic landscapes","volume":"7","author":"B Pereira","year":"2016","journal-title":"Nat Commun"},{"issue":"5","key":"pone.0242141.ref024","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1158\/2159-8290.CD-12-0095","article-title":"The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data","volume":"2","author":"E Cerami","year":"2012","journal-title":"Cancer Discov"},{"issue":"269","key":"pone.0242141.ref025","first-page":"pl1","article-title":"Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal","volume":"6","author":"J Gao","year":"2013","journal-title":"Sci Signal"},{"issue":"7","key":"pone.0242141.ref026","first-page":"14247","article-title":"Upregulation of fibronectin, vitronectin and claudin-7 in cervical cancer","volume":"9","author":"B Zhang","year":"2016","journal-title":"Int J Clin Exp Med"},{"issue":"1","key":"pone.0242141.ref027","first-page":"2527","article-title":"Evaluation of Vitronectin Expression in Prostate Cancer and the Clinical Significance of the Association of Vitronectin Expression with Prostate Specific Antigen in Detecting Prostate Cancer","volume":"13","author":"Y Niu","year":"2016","journal-title":"Urol J"},{"issue":"1","key":"pone.0242141.ref028","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1186\/s12885-019-5693-2","article-title":"Vitronectin as a molecular player of the tumor microenvironment in neuroblastoma","volume":"19","author":"R Burgos-Panadero","year":"2019","journal-title":"BMC Cancer"},{"issue":"7","key":"pone.0242141.ref029","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1007\/s00432-010-0974-9","article-title":"Identification of vitronectin as a novel serum marker for early breast cancer detection using a new proteomic approach","volume":"137","author":"M Kadowaki","year":"2011","journal-title":"J Cancer Res Clin Oncol"},{"issue":"7","key":"pone.0242141.ref030","doi-asserted-by":"crossref","first-page":"8909","DOI":"10.1007\/s13277-015-4750-y","article-title":"Vitronectin: a promising breast cancer serum biomarker for early diagnosis of breast cancer in patients","volume":"37","author":"W Hao","year":"2016","journal-title":"Tumour Biol"},{"key":"pone.0242141.ref031","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.semcancer.2019.06.002","article-title":"Akt in cancer: Mediator and more","volume":"59","author":"S Revathidevi","year":"2019","journal-title":"Semin Cancer Biol"},{"key":"pone.0242141.ref032","first-page":"951724","article-title":"Akt: a double-edged sword in cell proliferation and genome stability","volume":"2012","author":"N Xu","year":"2012","journal-title":"J Oncol"},{"issue":"4","key":"pone.0242141.ref033","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1177\/1758834014530023","article-title":"The PI3K\/AKT\/mTOR pathway in breast cancer: targets, trials and biomarkers","volume":"6","author":"E Paplomata","year":"2014","journal-title":"Ther Adv Med Oncol"},{"issue":"4","key":"pone.0242141.ref034","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1158\/1535-7163.MCT-08-0668","article-title":"Increased AKT S473 phosphorylation after mTORC1 inhibition is rictor dependent and does not predict tumor cell response to PI3K\/mTOR inhibition","volume":"8","author":"M Breuleux","year":"2009","journal-title":"Mol Cancer Ther"},{"issue":"9","key":"pone.0242141.ref035","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1038\/bjc.2012.107","article-title":"PI3K\/Akt signalling is required for the attachment and spreading, and growth in vivo of metastatic scirrhous gastric carcinoma","volume":"106","author":"T Matsuoka","year":"2012","journal-title":"Br J Cancer"},{"issue":"7","key":"pone.0242141.ref036","article-title":"Evaluation of Serum Integrin alphavbeta3 & Vitronectin in the Early Diagnosis of Breast Cancer","volume":"65","author":"AF Radwan","year":"2019","journal-title":"Clin Lab"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0242141","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,11,19]],"date-time":"2020-11-19T13:56:25Z","timestamp":1605794185000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0242141"}},"subtitle":[],"editor":[{"given":"Joe W.","family":"Ramos","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2020,11,19]]},"references-count":36,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2020,11,19]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0242141","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,11,19]]}}}